Lonza

Active Pharmaceutical Ingredients and High Potency API Industry Banks on API Portfolio - Grand View Research, Inc.

Retrieved on: 
화요일, 6월 6, 2023
Wuxi, Laboratory, Drug development, Production Linked Incentive schemes in India, Teva Active Pharmaceutical Ingredients, API, Lonza, CMOS, PDL, Cancer, Medicine, USD, ADL, Projection, Acquisition, Traction, Novartis, Investment, Quality control, SAN, Growth, Novasep, Mortality, American Cancer Society, FDA, Red Data Book of Ukraine, PLI, Fine chemical

SAN FRANCISCO, June 6, 2023 /PRNewswire/ -- The global active pharmaceutical ingredients and high potency API industry size stood at USD 233.31 billion in 2021 and is poised to observe a CAGR of 6% from 2022 to 2030, according to the " Active Pharmaceutical Ingredients and High Potency API Industry Data Book, 2023 – 2030 ," published by Grand View Research.

Key Points: 
  • SAN FRANCISCO, June 6, 2023 /PRNewswire/ -- The global active pharmaceutical ingredients and high potency API industry size stood at USD 233.31 billion in 2021 and is poised to observe a CAGR of 6% from 2022 to 2030, according to the " Active Pharmaceutical Ingredients and High Potency API Industry Data Book, 2023 – 2030 ," published by Grand View Research.
  • Besides, the adoption of a sedentary lifestyle and soaring cancer cases have propelled the development of API.
  • The global API market size was valued at USD 209.71 billion in 2021 and will exhibit a 5.9% CAGR between 2022 and 2030.
  • Order your copy of the Free Sample of "Active Pharmaceutical Ingredients and High Potency API Industry Data Book - Active Pharmaceutical Ingredients and High Potency Active Pharmaceutical Ingredients Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030" Data Book, published by Grand View Research
    Industry leaders are counting on the high efficiency of HPAPI molecules to solidify their position in the global landscape.

Active Pharmaceutical Ingredients and High Potency API Industry Banks on API Portfolio - Grand View Research, Inc.

Retrieved on: 
화요일, 6월 6, 2023
Wuxi, Laboratory, Drug development, Production Linked Incentive schemes in India, Teva Active Pharmaceutical Ingredients, API, Lonza, CMOS, PDL, Cancer, Medicine, USD, ADL, Projection, Acquisition, Traction, Novartis, Investment, Quality control, SAN, Growth, Novasep, Mortality, American Cancer Society, FDA, Red Data Book of Ukraine, PLI, Fine chemical

SAN FRANCISCO, June 6, 2023 /PRNewswire/ -- The global active pharmaceutical ingredients and high potency API industry size stood at USD 233.31 billion in 2021 and is poised to observe a CAGR of 6% from 2022 to 2030, according to the " Active Pharmaceutical Ingredients and High Potency API Industry Data Book, 2023 – 2030 ," published by Grand View Research.

Key Points: 
  • SAN FRANCISCO, June 6, 2023 /PRNewswire/ -- The global active pharmaceutical ingredients and high potency API industry size stood at USD 233.31 billion in 2021 and is poised to observe a CAGR of 6% from 2022 to 2030, according to the " Active Pharmaceutical Ingredients and High Potency API Industry Data Book, 2023 – 2030 ," published by Grand View Research.
  • Besides, the adoption of a sedentary lifestyle and soaring cancer cases have propelled the development of API.
  • The global API market size was valued at USD 209.71 billion in 2021 and will exhibit a 5.9% CAGR between 2022 and 2030.
  • Order your copy of the Free Sample of "Active Pharmaceutical Ingredients and High Potency API Industry Data Book - Active Pharmaceutical Ingredients and High Potency Active Pharmaceutical Ingredients Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030" Data Book, published by Grand View Research
    Industry leaders are counting on the high efficiency of HPAPI molecules to solidify their position in the global landscape.

Global Algaecides Market 2023 to 2028: Rising Incidences of Harmful Algal Blooms Drives Growth

Retrieved on: 
월요일, 5월 29, 2023
United States Environmental Protection Agency, Food, United States Department of Agriculture, Department of Science and Technology (Philippines), Research, Tilapia, Private, Statistics, Agriculture, Aquaculture, Lonza, Yearbook, Nutrient, Australian government debt, Temperature, Carbon, Salinity, Food and Agriculture Organization, Algal bloom, Climate change, ALSA, Investment, USDA, Pond, Male, Growth, Climate, Intensive word form, Geography, Nitrogen, Phosphorus, Fishery, Population growth, Lake, Fertilizer, Fine chemical

Thus, the expansion of the agricultural sector is expected to drive the demand for agricultural algaecides, thus augmenting market growth.

Key Points: 
  • Thus, the expansion of the agricultural sector is expected to drive the demand for agricultural algaecides, thus augmenting market growth.
  • The rise in the incidences of harmful algal blooms around the world, caused by various factors like the rise in climate change and industrial pollution is contributing towards the algaecides market growth.
  • With the rise in occurrences of algal blooms with, the growth of the algaecides market is likely to surge during the forecast period.
  • A well-established aquaculture market in the North American region is expected to drive the market of algaecides in this region.

Lonza Increases Straight Bond by CHF 150 Million

Retrieved on: 
목요일, 4월 20, 2023
Lonza, SIX Swiss Exchange, CHF, Cryptocurrency, Fine chemical

Basel, Switzerland, 20 April 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the increase of the Straight Bond issued on 8 February 2023 by CHF 150 million, in line with its financing plan for 2023.

Key Points: 
  • Basel, Switzerland, 20 April 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the increase of the Straight Bond issued on 8 February 2023 by CHF 150 million, in line with its financing plan for 2023.
  • The increment has the same maturity (6.5 years) and coupon (2.100%) as the initial issuance.
  • The issuer is Lonza Swiss Finance Ltd, Basel, and the bonds will be guaranteed by Lonza.
  • Lonza will apply for the listing of the bonds on the SIX Swiss Exchange.

KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO

Retrieved on: 
월요일, 4월 17, 2023
Data Management, Biotechnology, Technology, Manufacturing, Health, General Health, Pharmaceutical, Other Technology, Research, Other Manufacturing, Science, Lonza, Multimedia, JSR, KBI, Patient, Ecosystem, Management, Fine chemical, Genentech

KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies, today announced the appointment of J.D.

Key Points: 
  • KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies, today announced the appointment of J.D.
  • will lead KBI and Selexis into the next chapter of becoming a leader in the next generation of CDMOs that are emerging.
  • Mowery, KBI Biopharma and Selexis SA Chief Executive Officer (Photo: Business Wire)
    “Through decades of service, J.D.
  • will play a crucial role in leading KBI and Selexis and empowering our global teams to succeed through servant leadership.

Pharmaceutical Multinationals Continue To Spurn The Opportunity To Connect Via Social Media At A Local Level

Retrieved on: 
목요일, 4월 13, 2023
Consulting, Technology, Professional Services, Other Health, Other Communications, Health, Public Relations, Investor Relations, Pharmaceutical, Communications, Social Media, Apps, Applications, Astellas Pharma, Roche, Overalls, Lonza, HOW, Janssen, MCI Inc., Language, Express, Canonical form, Novartis, AbbVie, Novo Nordisk, Beckers, Sanofi, DEI, ESG, Takeda Pharmaceutical Company, ROI, Social media, Pfizer, Fine chemical, Sales, Marketing, TikTok, App, Merck

Serge Beckers, chairman of Worldcom Healthcare, said: “While the use of social media continues to increase, pharmaceutical firms continue to miss out on local engagement.

Key Points: 
  • Serge Beckers, chairman of Worldcom Healthcare, said: “While the use of social media continues to increase, pharmaceutical firms continue to miss out on local engagement.
  • App use has increased but visual platforms like YouTube and TikTok and mainstream social media platforms like Facebook, remain underutilized at a local level.
  • Pharma companies are missing the opportunity to convey, at a local level, how they satisfy heightened consumer expectations around topics such as DEI and ESG.
  • While all but two of the companies have a ‘global blog’, local blogs remain hard to find.

Nutraceutical Contract Manufacturing Services Global Market Report 2023: Expanding Healthcare Infrastructure and Demand for Personalized Nutrition Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
월요일, 4월 3, 2023
Pharmaceutical, Health, Fitness & Nutrition, HPMC, Food, Gencor, Drink, Prevalence, Nature's Sunshine Products, Lonza, Functional food, Research, USD, DSM (company), Tablet, Capsule, Patent, Dietary supplement, Economic development, Conditional sentence, Region, Probiotic, Pharmaceutical industry

The "Nutraceutical Contract Manufacturing Services Market By Dosage Form, By Product, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nutraceutical Contract Manufacturing Services Market By Dosage Form, By Product, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The nutraceutical contract manufacturing services market size is estimated to be USD 114.2 billion in 2022 and is expected to witness a CAGR of 12.01% during the forecast period 2023-2033.
  • Increasing health consciousness, growing need for personalized nutrition, increasing use of modern technology and expanding healthcare infrastructure are projected to drive the market growth in near future.
  • The expansion of the healthcare infrastructure and increased use of contemporary technology are anticipated to drive market growth throughout the anticipated timeframe.

LBB Specialties Appoints Senior Vice President for Food and Nutrition

Retrieved on: 
수요일, 4월 5, 2023
Product management, Council for Responsible Nutrition, Nutrition, Senior, Lonza, Under Secretary of Agriculture for Food, Nutrition, and Consumer Services, CRN, Logistics, Strategic planning, Marketing, Personal care, Human nutrition, Council, Supply, Hygiene, Food and Nutrition Service, LBB, Food, Gennaro (surname), Management, Fine chemical, Science

NORWALK, Conn., April 5, 2023 /PRNewswire/ -- LBB Specialties (LBBS), a leader in North American specialty chemical and ingredients distribution, announced Mike DeGennaro will join the company as Senior Vice President, Food and Nutrition.

Key Points: 
  • NORWALK, Conn., April 5, 2023 /PRNewswire/ -- LBB Specialties (LBBS), a leader in North American specialty chemical and ingredients distribution, announced Mike DeGennaro will join the company as Senior Vice President, Food and Nutrition.
  • LBB Specialties announced Mike DeGennaro will join the company as Senior Vice President, Food and Nutrition.
  • DeGennaro brings a wealth of experience to LBB Specialties that spans 25 years in specialty chemicals and ingredients.
  • "I am thrilled to be joining LBB Specialties as Senior Vice President, Food and Nutrition," said Mike DeGennaro.

LBB Specialties Appoints Senior Vice President for Food and Nutrition

Retrieved on: 
수요일, 4월 5, 2023
Product management, Council for Responsible Nutrition, Nutrition, Senior, Lonza, Under Secretary of Agriculture for Food, Nutrition, and Consumer Services, CRN, Logistics, Strategic planning, Marketing, Personal care, Human nutrition, Council, Supply, Hygiene, Food and Nutrition Service, LBB, Food, Gennaro (surname), Management, Fine chemical, Science

NORWALK, Conn., April 5, 2023 /PRNewswire/ -- LBB Specialties (LBBS), a leader in North American specialty chemical and ingredients distribution, announced Mike DeGennaro will join the company as Senior Vice President, Food and Nutrition.

Key Points: 
  • NORWALK, Conn., April 5, 2023 /PRNewswire/ -- LBB Specialties (LBBS), a leader in North American specialty chemical and ingredients distribution, announced Mike DeGennaro will join the company as Senior Vice President, Food and Nutrition.
  • DeGennaro will be responsible for establishing, implementing, and executing the business and commercial strategy for the Food and Nutrition vertical.
  • DeGennaro brings a wealth of experience to LBB Specialties that spans 25 years in specialty chemicals and ingredients.
  • "I am thrilled to be joining LBB Specialties as Senior Vice President, Food and Nutrition," said Mike DeGennaro.

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Retrieved on: 
수요일, 3월 22, 2023
Insurance, AACR, Liver function tests, CD3, Survival, Lonza, Clinical trial, LFT, Path integral molecular dynamics, Anastrozole, G&A, Research, CLDN6, Immunotherapy, Lung, American Association for Cancer Research, Patient, Immune system, Cancer, Context, Growth, R, IND, Female, Breast cancer, Pharmaceutical industry, Cryptocurrency, Vaccine, Fine chemical

PHILADELPHIA, March 22, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced financial results for the year ended December 31, 2022. Additionally, the Company announced a portfolio prioritization and capital allocation strategy that is expected to extend its cash runway into late 2024. The resulting changes include discontinuing the development of onapristone extended release (ONA-XR) and focusing on the development of CTIM-76, its Claudin 6 (CLDN6) bispecific antibody clinical candidate.

Key Points: 
  • PHILADELPHIA, March 22, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced financial results for the year ended December 31, 2022.
  • “We are shifting our development focus to our compelling preclinical asset CTIM-76, a CLDN6 x CD3 bispecific antibody.
  • ET, Context will host an investor R&D webinar with the Company’s management team and AACR presenter to discuss the presentation.
  • Context reported a net loss of $14.8 million for 2022, as compared to $10.5 million for the same period in 2021.